Background
Genome-wide association studies for coronary artery disease (CAD)/myocardial infarction (MI) revealed a 58kb risk locus on 9p21.3. Refined genetic analyses revealed unique haplotype blocks conferring susceptibility to atherosclerosis per se vs risk for acute complications in the presence of underlying CAD. The cell proliferation inhibitor locus, CDKN2A, maps just upstream of the MI risk block, is at least partly regulated by the non-coding RNA, ANRIL, overlapping the risk block, and has been associated with platelet (PLT) counts in humans. Thus, we tested the hypothesis that CDKN2A deficiency predisposes to increased PLT production leading to increased PLT activation in the setting of hypercholesterolemia.
Methods and Results
PLT production and activation were measured in B6-Ldlr−/−Cdkn2a+/− mice and a congenic strain carrying the region of homology with the human 9p21.3/CDKN2A locus. The strains exhibit decreased expression of CDKN2A (both p16INK4a and p19ARF) but not CDKN2B (p15INK4b). Compared to B6-Ldlr−/− controls, both Cdkn2a-deficient strains exhibited increased PLT counts and bone marrow megakaryopoiesis. The PLT over-production phenotype was reversed by treatment with cyclin-dependent kinase 4/6 inhibitor, PD0332991/palbociclib, that mimics the endogenous effect of p16INK4a. Western-diet feeding resulted in increased PLT activation, increased thrombin/anti-thrombin complex, and decreased bleeding times in Cdkn2a-deficient mice compared to controls.
Conclusions
Together, the data suggest that one or more Cdkn2a transcripts modulate PLT production and activity in the setting of hypercholesterolemia, amenable to pharmaceutical intervention. Enhanced PLT production and activation may predispose to arterial thrombosis, suggesting an explanation, at least in part, for the association of 9p21.3 and MI.